<DOC>
	<DOC>NCT01858389</DOC>
	<brief_summary>This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each two-week cycle to patients with Non-small cell lung cancer. The study includes two groups of patients, those whose tumor has a documented T790M mutation, and those without this mutation. All patients will receive repeated cycles of dacomitinib until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met.</brief_summary>
	<brief_title>A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Evidence of histologically confirmed, advanced NSCLC (stage IIIB/IV). Evidence of T790M mutation to enroll in Cohort A. Evidence of measurable disease by radiographic technique. Adequate organ function. Patients with T790M mutation who stopped any prior EGFRdirected therapy without evidence of disease progression. Symptomatic brain metastases. Uncontrolled or significant cardiovascular disease. Pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>T790M mutation. dacomitinib</keyword>
</DOC>